Serum early morning total T (TT) levels were measured at baseline and periodically after ADT cessation. Multivariable time-to-event analysis (Cox proportional hazards) was performed to determine predictors of TT recovery after ADT cessation and included the following variables: patient age, baseline T level, and duration of ADT.
INTRODUCTION AND OBJECTIVES: A registry was established to assess long-term effectiveness and safety of testosterone undecanoate injections (TU) in a urological setting in comparison to an untreated hypogonadal control group. Parameters related to renal function were measured to gain insight on effects of testosterone therapy (TTh) on renal function. METHODS: Observational, prospective, cumulative registry study in 505 men (age: 61.4 AE 9.7 years) with total testosterone (T) levels 350 ng/dL and symptoms of hypogonadism. 321 men received parenteral TU 1000 mg/12 weeks following an initial 6-week interval for up to 12 years (T-group). 184 men had opted against TTh and served as controls (CTRL). 8-year data were analyzed. Renal profile was assessed by (Creatinine, Urea, Uric acid and Glomerular filtration rate measured according to Mayo Clinic setting) RESULTS: Creatinine decreased from 1.14AE0.18 to 1.07AE0.8 mg/dL in the T-group and increased from 0.99AE0.25 to 1.13AE0.53 in CTRL. Uric acid decreased from 6.8AE1.5 to 5.5AE1.6 mg/dL in the T-group (p<0.0001) and from 5.7AE1.5 to 5.2AE1.5 mg/dL in CTRL (p<0.01). Urea was only available for the T-group and decreased from 47.5AE12.0 to 31.7AE12.9 mg/dL (p<0.0001). Glomerular filtration rate (GFR) increased from 86.6AE12.8 to 98.5AE8.6 mL/min/1.73 m2 in the T-group and decreased from 90.8AE20.2 to 87.0AE26.0 mL/min/1.73 m2 in CTRL (p<0.0001 for both). g-GT decreased from 39.31AE11.62 to 28.95AE7.57 U/L in the T-group (p<0.0001) and increased from 37.79AE29.55 to 39.5AE26.71 U/L in CTRL (p<0.0005). Bilirubin decreased from 1.64AE4.13 to 1.21AE1.89 mg/dL in the T-group (p<0.05) and increased from 1.04AE7.08 to 1.12AE1.96 mg/dL in CTRL (NS). AST remained stable in both groups, ALT declined slightly in both groups. Medication adherence in the T-group was 100 per cent as all injections were administered in the office and documented. There were 25 deaths (7.8%) in the T-group of which 11 (44%) were cardiovascular. In CTRL, 28 patients (15.2%) died, and all deaths (100%) were attributed to cardiovascular causes.
CONCLUSIONS: Long-term TTh with TU in an unselected hypogonadal men resulted in improvement of renal function, whereas there was a slight worsening in untreated controls. Since renal function may be related to cardiovascular risk, the observed changes may have contributed to a reduction in mortality. METHODS: Registry study in 656 men with testosterone 350 ng/dL and hypogonadal symptoms. 360 received TU 1000 mg/12 weeks following an initial 6-week interval (T-group). 296 men opted against TTh and served as controls (CTRL). 8-year data are presented. Changes over time between groups were compared by a mixed effects model for repeated measures with a random effect for intercept and fixed effects for time, group and their interaction. Changes were adjusted for age, weight, waist circumference, blood pressure, fasting glucose, lipids and quality of life to account for baseline differences between groups. In order to further validate results, propensity matching was performed for baseline age, BMI, and waist circumference. 82 men in each group fulfilled criteria. RESULTS: Total group: mean age was 57.4AE7.3 years in the T-group and 64.8AE4.3 in CTRL, median follow-up time 7 years for both. In the T-group, T levels rose from 285AE37 ng/dL to trough levels (measured prior to the following injection) between 450 and 500 ng/dL (p<0.0001). In CTRL, T levels remained stable between 260 and 280 ng/dL. In the T group, IIEF-EF (maximum score: 30) increased from 19.5AE5.0 to 25.9AE3.0 with a change from baseline of 6.0 points. The improvement was statistically significant for the first four years and remained statistically significant vs baseline throughout the observation time and stable compared to previous years. In the CTRL group, IIEF-EF decreased from 20.5AE3.1 to 11.7AE1.6 after 8 years by 9.5 points (p<0.0001 for both). Propensity-matched group: mean age was 61.7AE5.1 years in the T-group and 61.6AE2.9 in CTRL, median follow-up time 8 years in the T-group and 7 in CTRL. In the T-group, T levels rose from 277AE41 ng/dL to trough levels between 470 and 515 ng/dL (p<0.0001). In CTRL, T levels remained stable between 250 and 280 ng/dL. In the T group, IIEF-EF (maximum score: 30) increased from 19.5AE5.6 to 25.8AE3.9 with a change from baseline of 5.9 points. The improvement was statistically significant for the first three years and remained statistically significant vs baseline throughout the observation time and stable compared to previous years. In CTRL, IIEF-EF decreased from 20.2AE3.3 to 12.4AE1.0 after 8 years by 8.6 points (p<0.0001 for both).
Source of
CONCLUSIONS: Erectile function is improved and preserved for a prolonged period of time by TTh in hypogonadal men and deteriorates in untreated hypogonadal men.
Source of Funding: Bayer Pharma AG partially funded data entry and statistical analyses.
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